论文部分内容阅读
口服抗糖尿病药物的研发不断取得成功,已经上市的有噻唑烷二酮类、胰高糖素样肽1受体激动剂、二肽基肽酶Ⅳ抑制剂和胰淀素类似物等,正在进行研究的有葡萄糖激酶激活剂、钒复合物和生物活性铬等。原有的药物也在剂型上不断改进,控释剂、缓释剂和复方型逐渐出现。这些研究的成功为糖尿病的治疗提供更多的手段,以期达到更好的治疗效果。
Ongoing success in the development of oral antidiabetic drugs is already under way with thiazolidinediones, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase IV inhibitors and amylin analogues, which are on the way Study of glucokinase activators, vanadium complexes and bioactive chromium and so on. The original drug is also on the continuous improvement of formulations, controlled release agents, sustained release agents and compound type gradually appear. The success of these studies provides more tools for the treatment of diabetes in order to achieve better therapeutic results.